WSO December 2023 – Issue 3 - 1197

Thorén et al.
1197
Table 1. (Continued)
All
Characteristic
Hyperlipidemia (%)
Smoker (%)
Never
Previous
Current
Aspirin treatment (%)
Clopidogrel treatment (%)
Other antiplatelet treatment (%)
Statin treatment (%)
Oral hypertensive medication (%)
Oral antidiabetic medication (%)
Insulin treatment (%)
IVT (%)
Stroke onset to end of thrombectomy,
min (mean)
Stroke unit care (%)
Vascular territory (%)
Left
Right
Bilateral
Chi-square test or t test was used as appropriate.
n
4603 36.2
3403 77.1
372
8.4
639 14.5
4589 25.5
4594
4595
No or mild CED at 24 h
Mean (SD) or % n
3916 35.7
2903 77.2
319
8.5
5.7
1.3
4577 31.3
4585 66.4
4596 13.5
4597
4.1
4280 61.3
4018 314 (165)
4640 83.9
2245 52.2
2019 46.9
37
0.9
539 14.3
3909 25.5
3913
3913
Moderate or severe
CED at 24 h
Mean (SD) or % n
Mean (SD) or %
687 39.2
500 76.6
53
8.1
5.6
1.4
3899 30.8
3906 67.0
3915 12.7
3915
4.0
3947 62.2
3434 310 (166)
3947 84.4
1921 52.8
1691 46.5
25
0.7
100 15.3
680 25.4
681
682
6.2
0.9
678 34.4
679 63.2
681 17.6
682
4.5
693 56.1
584 336 (157)
693 81.5
324 48.8
328 49.4
12
1.8
0.99
0.53
0.31
0.06
0.05
<0.05
0.54
<0.05
<0.05
0.06
<0.05
p
0.08
0.78
diabetes (24% vs 20%). Moderate or severe CED was less
frequent among patients that had successful reperfusion
compared to patients without reperfusion: 12.5% versus
29.6%, p < 0.05, crude RR (cRR) 0.42 (95% CI: 0.37-
0.49). Univariable risks for moderate or severe CED, by
individual characteristics, are shown in the online supplemental
material.
Table 2 shows risks for moderate or severe CED resulting
from the adjusted models. In patients with successful
reperfusion, adjusted RR (aRR) for moderate or severe
CED was 0.50 (0.44-0.57) with an area under the curve
(AUC) of 0.75. Compared to patients with mTICI 0 or 1,
aRR for moderate or severe CED in patients with progressively
higher mTICI grades were: for mTICI 2a, aRR 1.24
(1.01-1.54); for mTICI 2b, aRR 0.67 (0.55-0.82); and for
mTICI 3, aRR 0.49 (0.41-0.60) with AUC 0.75. In successfully
reperfused patients, adding PH to the model increased
aRR from 0.50 to 0.63 (0.55-0.72), indicating that about
one-fourth of the protective effect of successful reperfusion
was lost. Meanwhile, successfully reperfused patients had
less parenchymal hemorrhage compared to non-reperfused
(8.6% vs 12.7%, p < 0.05). To demonstrate the extent of
effect modification, separate models were run stratifying
by SHS and P-SHS. As seen in Table 3, and presented in
detail in the online supplemental material, the aRR for CED
with reperfusion was 0.32 (0.24-0.42) among patients
without SHS and 0.56 (0.48-0.66) among patients with
SHS with corresponding aRR for P-SHS 0.36 (0.25-0.53)
and 0.81 (0.69-0.95). This indicated that the association
between reperfusion and lower risk of CED, interpreted as
International Journal of Stroke, 18(10)

WSO December 2023 – Issue 3

Table of Contents for the Digital Edition of WSO December 2023 – Issue 3

Contents
WSO December 2023 – Issue 3 - Cover1
WSO December 2023 – Issue 3 - Cover2
WSO December 2023 – Issue 3 - 1143
WSO December 2023 – Issue 3 - Contents
WSO December 2023 – Issue 3 - 1145
WSO December 2023 – Issue 3 - 1146
WSO December 2023 – Issue 3 - 1147
WSO December 2023 – Issue 3 - 1148
WSO December 2023 – Issue 3 - 1149
WSO December 2023 – Issue 3 - 1150
WSO December 2023 – Issue 3 - 1151
WSO December 2023 – Issue 3 - 1152
WSO December 2023 – Issue 3 - 1153
WSO December 2023 – Issue 3 - 1154
WSO December 2023 – Issue 3 - 1155
WSO December 2023 – Issue 3 - 1156
WSO December 2023 – Issue 3 - 1157
WSO December 2023 – Issue 3 - 1158
WSO December 2023 – Issue 3 - 1159
WSO December 2023 – Issue 3 - 1160
WSO December 2023 – Issue 3 - 1161
WSO December 2023 – Issue 3 - 1162
WSO December 2023 – Issue 3 - 1163
WSO December 2023 – Issue 3 - 1164
WSO December 2023 – Issue 3 - 1165
WSO December 2023 – Issue 3 - 1166
WSO December 2023 – Issue 3 - 1167
WSO December 2023 – Issue 3 - 1168
WSO December 2023 – Issue 3 - 1169
WSO December 2023 – Issue 3 - 1170
WSO December 2023 – Issue 3 - 1171
WSO December 2023 – Issue 3 - 1172
WSO December 2023 – Issue 3 - 1173
WSO December 2023 – Issue 3 - 1174
WSO December 2023 – Issue 3 - 1175
WSO December 2023 – Issue 3 - 1176
WSO December 2023 – Issue 3 - 1177
WSO December 2023 – Issue 3 - 1178
WSO December 2023 – Issue 3 - 1179
WSO December 2023 – Issue 3 - 1180
WSO December 2023 – Issue 3 - 1181
WSO December 2023 – Issue 3 - 1182
WSO December 2023 – Issue 3 - 1183
WSO December 2023 – Issue 3 - 1184
WSO December 2023 – Issue 3 - 1185
WSO December 2023 – Issue 3 - 1186
WSO December 2023 – Issue 3 - 1187
WSO December 2023 – Issue 3 - 1188
WSO December 2023 – Issue 3 - 1189
WSO December 2023 – Issue 3 - 1190
WSO December 2023 – Issue 3 - 1191
WSO December 2023 – Issue 3 - 1192
WSO December 2023 – Issue 3 - 1193
WSO December 2023 – Issue 3 - 1194
WSO December 2023 – Issue 3 - 1195
WSO December 2023 – Issue 3 - 1196
WSO December 2023 – Issue 3 - 1197
WSO December 2023 – Issue 3 - 1198
WSO December 2023 – Issue 3 - 1199
WSO December 2023 – Issue 3 - 1200
WSO December 2023 – Issue 3 - 1201
WSO December 2023 – Issue 3 - 1202
WSO December 2023 – Issue 3 - 1203
WSO December 2023 – Issue 3 - 1204
WSO December 2023 – Issue 3 - 1205
WSO December 2023 – Issue 3 - 1206
WSO December 2023 – Issue 3 - 1207
WSO December 2023 – Issue 3 - 1208
WSO December 2023 – Issue 3 - 1209
WSO December 2023 – Issue 3 - 1210
WSO December 2023 – Issue 3 - 1211
WSO December 2023 – Issue 3 - 1212
WSO December 2023 – Issue 3 - 1213
WSO December 2023 – Issue 3 - 1214
WSO December 2023 – Issue 3 - 1215
WSO December 2023 – Issue 3 - 1216
WSO December 2023 – Issue 3 - 1217
WSO December 2023 – Issue 3 - 1218
WSO December 2023 – Issue 3 - 1219
WSO December 2023 – Issue 3 - 1220
WSO December 2023 – Issue 3 - 1221
WSO December 2023 – Issue 3 - 1222
WSO December 2023 – Issue 3 - 1223
WSO December 2023 – Issue 3 - 1224
WSO December 2023 – Issue 3 - 1225
WSO December 2023 – Issue 3 - 1226
WSO December 2023 – Issue 3 - 1227
WSO December 2023 – Issue 3 - 1228
WSO December 2023 – Issue 3 - 1229
WSO December 2023 – Issue 3 - 1230
WSO December 2023 – Issue 3 - 1231
WSO December 2023 – Issue 3 - 1232
WSO December 2023 – Issue 3 - 1233
WSO December 2023 – Issue 3 - 1234
WSO December 2023 – Issue 3 - 1235
WSO December 2023 – Issue 3 - 1236
WSO December 2023 – Issue 3 - 1237
WSO December 2023 – Issue 3 - 1238
WSO December 2023 – Issue 3 - 1239
WSO December 2023 – Issue 3 - 1240
WSO December 2023 – Issue 3 - 1241
WSO December 2023 – Issue 3 - 1242
WSO December 2023 – Issue 3 - 1243
WSO December 2023 – Issue 3 - 1244
WSO December 2023 – Issue 3 - 1245
WSO December 2023 – Issue 3 - 1246
WSO December 2023 – Issue 3 - 1247
WSO December 2023 – Issue 3 - 1248
WSO December 2023 – Issue 3 - 1249
WSO December 2023 – Issue 3 - 1250
WSO December 2023 – Issue 3 - 1251
WSO December 2023 – Issue 3 - 1252
WSO December 2023 – Issue 3 - 1253
WSO December 2023 – Issue 3 - 1254
WSO December 2023 – Issue 3 - 1255
WSO December 2023 – Issue 3 - 1256
WSO December 2023 – Issue 3 - 1257
WSO December 2023 – Issue 3 - 1258
WSO December 2023 – Issue 3 - 1259
WSO December 2023 – Issue 3 - 1260
WSO December 2023 – Issue 3 - Cover3
WSO December 2023 – Issue 3 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com